EGY, GNS and OTLK among pre-market losers
Outlook Therapeutics plummets 78%, FibroGen declines 23%, and other stocks see significant drops after various earnings releases and study results, while UP Fintech Holding reports positive Q2 results.
Topics
Posted 8/30/2023, 12:24:12 PM
seekingalpha.com
Relevant topic timeline:
The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' experimental eye disease drug due to manufacturing issues observed during inspections, causing the company's shares to plummet by 78%.
Biopharmaceutical company Outlook Therapeutics experienced a significant decline in stock value after the FDA issued a letter stating that it could not approve the company's application for an investigational drug due to various issues and a lack of evidence.